

PATENT NUMBER

## U.S. UTILITY Patent Application

4 O.I.P.E.

PATENT DATE

SCANNED

**Q.A**

APPLICATION NO. 09/655272	CONT/PRIOR D F	CLASS 435	SUBCLASS	ART UNIT 1645	EXAMINER
------------------------------	-------------------	--------------	----------	------------------	----------

## APPLICANTS

Eric Moore  
Michael Fink  
Michael Leasure  
Eric John Leasure

# STUDY

Neurotransmitter-mediated activation of  $\text{Ca}^{2+}$  channels is activatable by phosphorylation. <sup>6</sup> It, thus, is the use of said channels in drug screening.

PTO-2040  
12/99

**ISSUING CLASSIFICATION**

[illegible]

Continued on Issue Slip Inside File Jacket

<input type="checkbox"/> <b>TERMINAL DISCLAIMER</b>	<b>DRAWINGS</b>		<b>CLAIMS ALLOWED</b>	
	Sheets Drwg.	Figs. Drwg.	Print Fig.	Total Claims
The term of this patent subsequent to _____ (date) has been disclaimed.	_____ (Assistant Examiner) _____ (Date)		<b>NOTICE OF ALLOWANCE MAILED</b>	
	The term of this patent shall not extend beyond the expiration date of U.S. Patent. No. _____  _____  _____		<b>ISSUE FEE</b>	
Amount Due			Date Paid	
The terminal ____ months of this patent have been disclaimed.	_____ (Primary Examiner) _____ (Date)		<b>ISSUE BATCH NUMBER</b>	
	_____ (Legal Instruments Examiner) _____ (Date)			
<b>WARNING:</b> The information disclosed herein may be restricted. Unauthorized disclosure may be prohibited by the United States Code Title 35, Sections 122, 181 and 368. Possession outside the U.S. Patent & Trademark Office is restricted to authorized employees and contractors only.				

Form **PTO-436A**  
(Rev. 6/99)

FILED WITH: ☐ DISK (CRF) ☐ FICHE ☐ CD-ROM  
(Attached in pocket on right inside flap)

(FACE)